Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
STAMPEDE (M0 high-risk): 2yr abiraterone on ADT+RT cuts MFS HR 0.53 (6yr 82% vs 69%), OS HR 0.60; adding enzalutamide gains nothing.
Prostate carried the day: 2yr abiraterone added to definitive ADT+RT in high-risk M0 disease (85% RT'd, 74Gy/37fx) drove MFS HR 0.53 and OS HR 0.60. Enzalutamide on top added tox for no extra MFS (HR 1.02). RT-attributable subgroup HR not broken out in source.
read the full digest →Studies · 101
- STAMPEDE (abiraterone ± enzalutamide, high-risk non-metastatic)MFS HR 0.53 (6yr 82% vs 69%) and OS HR 0.60 adding 2yr abiraterone to ADT in high-risk M0 prostate (85% also had RT).
- TREASUREmOS 6.7 vs 13.4mo (HR 1.55, ns) adding consolidative TRT to atezo maintenance; halted early for SAEs 61% vs 18%.
- EANO Consensus Statement on Radiation NecrosisDelphi consensus (20 experts): 53/57 statements reached ≥80% agreement; perfusion MRI + amino-acid PET to distinguish RN from recurrence, bevacizumab for steroid-refractory RN.
- HYDRANo PFS difference vs conventional RT for either MHFRT type, but dose-escalated MHFRT alone raised late G2+ GI + bowel-QoL decrement; isodose 60/20 clean.
- ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate CancerModern 5-fraction SBRT (1-2% bothersome toxicity vs 10-30% for 2D-era 45fx) is now NCCN-endorsed for UIR prostate; focal-boost de-escalation is next.
- SUPREMO10yr chest-wall recurrence 1.1% vs 2.5% (HR 0.45), no DFS/OS gain, but trial prohibited RNI so tests incomplete PMRT.
- ESTRO Oral Cavity CTV Delineation GuidelinesNew consensus recipe for post-op CTV: recreate pre-op GTV-P +10mm composited with surgical defect/flap +5mm; standardizes OCSCC delineation at EQD2 60 Gy.
- 10-yr SBRT for Prostate Cancer (Meier Nonrandomized Trial)10-yr OS 84%, RFS 90% (94% LR, 86% IR); late G3 GU/GI ≤1.5%, no G4-5; 40Gy/5fx SBRT, no ADT, 21 centers
- American Radium Society AUC: Intraprostatic Recurrence After RTPSMA PET + mpMRI plus mandatory pre-salvage biopsy, then reirradiation (≤6 fx) over ADT alone, for radiorecurrent intraprostatic disease.
- NRG-GU005DFS superiority not met (HR 1.38, futility crossed); SBRT improved 2y bowel QoL (35% vs 44% MCID decline, p=0.034) vs MH-IMRT.
- SUPREMO10-yr OS 81.4% vs 81.9% (HR 1.04, P=0.80): chest-wall RT gives no OS benefit in intermediate-risk post-mastectomy breast cancer.
- ARTOmOS NR vs 50mo, HR 0.55 (0.33-0.92, p=0.021) adding SBRT to all mets to abi+ADT in oligomet CRPC (unplanned OS analysis).